Table 3 Thresholds used to define abnormal in patients with COPD
From: B-type natriuretic peptides in chronic obstructive pulmonary disease: a systematic review
| Â | Natriuretic peptide | Threshold (pg/ml) | Method of selecting threshold | Proportion elevated (%) |
|---|---|---|---|---|
Stable | ||||
Inoue [35] | BNP | 34 | 2 SD from mean of normal control | 37 |
Bozkanat [28] | BNP | 36 | investigator selection | nr |
Rutten [24] | BNP NT–BNP | 35 125 | ROC curve | 49 51 |
Watz [30] | NT–BNP | 125 | manufacturer reference range | 23 |
van Gestel [49] | NT–BNP | 500 | cited review article (Jelic 2006) [87] | 17 |
Macchia [26] | NT–BNP | 160 | median | nr |
Andersen [42] | NT–BNP | 95 | ROC for echo pulmonary hypertension | 71 |
Anar [29] | NT–BNP | 125/450 (age specific) | manufacturer reference range | 15 |
Rubinsztajn [77] | NT–BNP | 125 | manufacturer reference range | 44 |
Ozdemirel [19] | NT–BNP | 84/155 (gender specific) | nr | nr |
Exacerbation | ||||
Lee [51] | BNP | 88 | ROC for survival | 39 |
Gariani [47] | BNP | 500 | guidelines | 30 |
Abroug [46] | NT–BNP | 1000 and 2500 | ROC rule out and in LV dysfunction | nr |
Sanchez-Marteles [88] | NT–BNP | 500 | ROC for survival | 53 |
Chang [44] | NT–BNP | 220 pmol/l | local laboratory (also Lee 13) [37] | 27 |
Hoiseth [45] | NT–BNP | 2500 | based on Abroug [46] | 18 |
Marcun [34] | NT–BNP | – | age/sex adjusted 95 percentile | 60 |
Ouanes [43] | NT–BNP | 1000/2000 (renal specific) | ROC for LV dysfunction | nr |
Lee [37] | NT–BNP | 220 pmol/l | local laboratory (also Chang 11) [44] | 44 |
Wang [32] | NT–BNP | 935 | ROC for LV dysfunction | nr |
Patel [38] | NT–BNP | 220 pmol/l | based on Chang [44] | 16 |
El Mallawany [39] | NT–BNP | 900 | ROC for LV dysfunction | nr |